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Abstract
Background: The CONSORT statement specifies the need for a balanced presentation of both
benefits and harms of medical interventions in trial reports. However, invitations to screening and
newspaper articles often emphasize benefits and downplay or omit harms, and it is known that
scientific articles can be influenced by conflicts of interest. We wanted to determine if a similar
imbalance occurs in scientific articles on mammography screening and if it is related to author
affiliation.
Methods: We searched PubMed in April 2005 for articles on mammography screening that
mentioned a benefit or a harm and that were published in 2004 in English. Data extraction was
performed by three independent investigators, two unblinded and one blinded for article contents,
and author names and affiliation, as appropriate. The extracted data were compared and
discrepancies resolved by two investigators in a combined analysis. We defined three groups of
authors: (1) authors in specialties unrelated to mammography screening, (2) authors in screening-
affiliated specialties (radiology or breast cancer surgery) who were not working with screening, or
authors funded by cancer charities, and (3) authors (at least one) working directly with
mammography screening programmes. We used a data extraction sheet with 17 items described
as important benefits and harms in the 2002 WHO/IARC-report on breast cancer screening.
Results: We identified 854 articles, and 143 were eligible for the study. Most were original
research. Benefits were mentioned more often than harms (96% vs 62%, P < 0.001). Fifty-five (38%)
articles mentioned only benefits, whereas seven (5%) mentioned only harms (P < 0.001).
Overdiagnosis was mentioned in 35 articles (24%), but was more often downplayed or rejected in
articles that had authors working with screening, (6/15; 40%) compared with authors affiliated by
specialty or funding (1/6; 17%), or authors unrelated with screening (1/14; 7%) (P = 0.03). Benefits
in terms of reduced breast cancer mortality were mentioned in 109 (76%) articles, and was more
often provided as a relative risk reduction than an absolute risk reduction, where quantified (45
articles (31%) versus 6 articles (3%) (P < 0.001)).
Conclusion: Scientific articles tend to emphasize the major benefits of mammography screening
over its major harms. This imbalance is related to the authors' affiliation.
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Background
It is essential to consider both benefits and harms care-
fully when the merits of any intervention are discussed in
the medical literature. This was recently emphasised in an
extension to the CONSORT statement on reporting ran-
domised trials [1], but it also applies to other scientific
work, and to information material directed towards
healthy citizens and patients [2]. However, the harms of
breast cancer screening are often downplayed or left
unmentioned in information materials, thus providing an
inadequate basis for informed decision-making [3-7]. A
similar bias has been found in newspaper articles on
breast cancer screening [8]. This focus on benefits is con-
trary to the ethical imperative that those subjected to any
preventive measure or treatment should receive unbiased
information [2], and it is particularly troublesome in
screening, as this is directed towards healthy individuals,
not patients seeking treatment. The 2002 WHO/IARC
report on breast cancer screening notes that "...the vast
majority of women undergoing screening do not have
breast cancer at the time of the examination, and these
women cannot derive a direct health benefit from screen-
ing; they can only be harmed" [9].
This report also notes that "An obvious source of harm
associated with any screening programme is unnecessary
treatment of cancers that were not destined to cause symp-
toms" [9] and that "Overdiagnosis refers to the detection
of cancers that would never have been found were it not
for the screening test. Patients in whom such indolent
cancers are detected do not benefit from screening and
can only experience harm: the worry associated with a
cancer diagnosis and the complications of therapy" [9].
Overtreatment is the treatment of such lesions. Overdiag-
nosis is different from identification of false positive
cases, which refers to women recalled for further testing
who do not have a suspicion of cancer confirmed. We
were particularly interested in the issue of overdiagnosis
as it markedly influences the life of women who experi-
ence it, could affect a substantial number of women [10],
and because it is not mentioned in invitations to screen-
ing [7].
We were also interested in the potential conflicts of inter-
est, including the medical specialties of the authors
[11,12]. A relationship between conclusions and conflicts
of interest has been demonstrated for passive smoking
[13], anti-inflammatory drugs in rheumatoid arthritis
[14], spinal manipulation [15], interventions to reduce
allergens from house dust mites [16] and cardiovascular
trials [17]. Authors also prefer references that support
their preconceived opinions [18,19].
We examined articles in medical journals discussing
mammography screening to see if they gave equal atten-
tion to benefits and harms, as we suspected that informa-
tion materials and newspaper articles would reflect their
presentation of the issues. We also explored the affiliation
and source of funding of the authors to examine if they
were associated with the likelihood of mentioning, or the
framing of, benefits and harms. We experienced some
challenges that led to supplementary analyses, which we
also report.
Methods
We included all articles on mammography screening that
described a benefit or a harm, or both, that were pub-
lished in English in 2004 and were identified in a compre-
hensive PubMed search; (exp breast neoplasm/all OR
"breast cancer" OR exp mammography/all OR mammo-
graph*) AND (exp mass screening/all OR screen*). We
excluded articles on mammographic techniques, assess-
ments of methodological approaches to evaluate screen-
ing, letters, and articles written by ourselves. The PubMed
search was performed in April 2005 and was limited to
articles published in 2004 to obtain a manageable sample
size that was as up to date as possible. Two investigators
read titles and abstracts independently. Potentially eligi-
ble articles were collected in hardcopy and read in full.
Data extraction was performed in parallel and independ-
ently by the three authors. One author (PG) was blinded
to author affiliation when evaluating contents, and
blinded to contents when evaluating author affiliation.
The other two authors (KJJ and AK) were not blinded.
Blinding was obtained by cutting out all information
from the article on author names, affiliation and funding,
and presenting this information separately from the con-
tents. The blinded author noted all instances where he
thought he could guess who the authors were or to which
conflict of interest category they belonged (see below).
Extracted data from the two unblinded authors were com-
pared and consensus reached where there was disagree-
ment ("unblinded consensus"). Subsequently, unblinded
consensus data and data from the blinded extraction were
compared and conflicts resolved by two of the authors
(KJJ and PG) using the blinded material for reference. We
analyzed our data in three ways: (1) data extracted by the
blinded author, (2) data extracted by unblinded authors,
(3) data combined from all three authors. This analysis
will be referred to as the "combined analysis".
We extracted data on 17 items described as important
benefits and harms in the 2002 WHO/IARC-report on
breast cancer screening and used their definitions [9]
(Table 1). For our primary analysis addressing whether
potential benefits and harms of mammography screening
were mentioned, we classified articles as: (1) only benefits
mentioned, (2) only harms mentioned, (3) both benefits
and harms mentioned. Mentioning one benefit or oneBMC Medicine 2007, 5:12 http://www.biomedcentral.com/1741-7015/5/12
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harm was considered sufficient for our labelling. We also
classified the framing of the discussion of harms as "men-
tioning harms", "acknowledging harms", or as "down-
playing harms". An article mentioning one or more
harms, in any way, would be labelled as "mentioning
harms". Some of these were also labelled as "downplaying
harms", because they used framing that made the harm
seem unimportant, e.g. by describing it as negligible or
non-existent (see Additional file 1 for examples). Those
who did not downplay harms by framing were considered
to acknowledge them.
We classified articles in three author affiliation categories:
(1) articles where all authors were in specialties unrelated
to mammography screening, (2) authors in screening-
affiliated specialties (radiology or breast cancer surgery)
who were not working with screening, or authors funded
by cancer charities, or (3) articles where at least one
author worked directly with mammography screening. In
many cases, author affiliation was not clear from the arti-
cles, or it was not clear if the institution employing the
author performed screening. We therefore retrieved addi-
tional information from the Internet for our combined
analysis. We were not able to find this for all authors,
however, and these cases were labelled as not being affili-
ated with screening.
During our study, we realised that a blinded data extrac-
tion would be necessary to guard against bias pertaining
to knowledge of author names or affiliation while evalu-
ating if a particular harm was downplayed or acknowl-
edged. Conversely, knowing the contents of an article
could potentially influence our evaluation of author affil-
iation. In a few cases, we knew the author had previously
worked with screening. If such articles were sceptical
towards screening, we could be prone to label the author
affiliation according to current status, and conversely if
the article was supportive of screening. We therefore took
care not to let our knowledge of the authors influence our
judgments, and used the authors' current affiliation in all
cases.
We used a chi-square test for trend [20] to compare the
three conflict of interest groups for potential differences in
the emphasis on benefits and harms, and a sign test to
compare mutually exclusive events in the same group that
would be expected to be similarly distributed in the
absence of a preference for either when exploring poten-
tial differences among author affiliation groups in the
number of times the separate 17 items were mentioned
and acknowledged.
Results
Our PubMed search yielded 854 titles and abstracts, 159
of which were considered eligible for further review and
collected in hardcopy for assessment. Sixteen were subse-
quently discarded, 13 because they were letters and three
because the affiliation of the author could not be estab-
lished. Hence, 143 articles were evaluated. Original
research articles predominated, and there was only minor
variation between author groups regarding the type of
article (original research, editorial, etc.; Table 2). Unless
stated otherwise, all results relate to analyses using the
combined data for all three authors.
Most authors preferred to focus on the benefits of mam-
mography screening, which were mentioned more often
than harms (96% vs. 62%, P < 0.001; Table 3). Fifty-five
articles (38%) mentioned only benefits, whereas 7 (5%)
mentioned only harms (P < 0.001). The benefit men-
tioned most often was a reduction in breast cancer mortal-
ity (109 articles, 76%). This benefit was more commonly
presented as a relative risk reduction than as an absolute
risk reduction, where quantified (45 articles, 31%, versus
6 articles, 3%)(P < 0.001). Five articles mentioned both
the absolute and relative risk reduction, and one the abso-
lute risk reduction only.
Overall, authors working with screening mentioned and
acknowledged harms less often than authors not working
with screening (29% vs. 40%) but the difference was not
statistically significant. Most of the separate 17 items we
Table 1: Benefits and harms of mammography screening 
included in our data extraction sheet and mentioned as 
important in the 2002 WHO/IARC report on mammography 
screening [9]
Benefits
Breast cancer mortality reduction
Relative risk reduction
Absolute risk reduction
Survival time from diagnosis
Number needed to screen
Carcinoma in situ, as positive
Less mastectomies/more tumourectomies
Total mortality reduction
Other
Harms
Overdiagnosis and overtreatment
Recall rate:
1. Per screen
2. Cumulative
More mastectomies/more tumourectomies
Increased biopsy rate
Risks associated with additional radiotherapy
Psychological effects related to false positives
Carcinoma in situ, as negative
Pain at mammography
OtherBMC Medicine 2007, 5:12 http://www.biomedcentral.com/1741-7015/5/12
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assessed were mentioned too rarely to draw any conclu-
sions regarding a possible relationship with author affili-
ation, although there were a few exceptions. We found a
trend that authors working with screening were less likely
than other authors to acknowledge overdiagnosis and
overtreatment (Figure 1) (P = 0.06). We also consistently
found that, when they mentioned it, authors working
with screening were more likely than other authors to
downplay or reject overdiagnosis and overtreatment (Fig-
ure 2), and this result was statistically significant in all
analyses (P = 0.03). However, the number of events was
small. We considered overdiagnosis and overtreatment to
be downplayed when described as negligible or non-exist-
ent (See Additional file 1 for examples). Other down-
played harms were described as barriers to participation in
screening rather than as negative consequences for the
women. This was mainly the case when authors described
harms such as recalls for further investigation, psycholog-
ical distress following false positive findings, and pain.
These harms could be barriers to participation, but it is
not their most important attribute.
Blinding appeared to be effective. In only 16 cases did the
blinded observer guess the identity of the authors, or an
author's affiliation, and in only one case might this have
influenced the judgments of the reported benefits and
harms, as the other 15 cases were unambiguous.
Discussion
We found that scientific articles tend to emphasize the
benefits of mammography screening over the harms. The
focus on benefits carries a risk of underestimating harms
and is in conflict with guidelines on reporting outcomes
of medical interventions [1]. Invitations to screening,
information material, and newspaper articles have all
been demonstrated to present information biased in
favour of screening [3-7] As they are all likely to reflect the
views presented in the scientific literature, our results
could explain a similar focus on benefits in those areas.
Failure to cover harms in invitations has serious ethical
implications and violates requirements for informed con-
sent [2]. Guidelines on how to develop balanced decision
aids exists, and use of such guidelines could help improve
the quality of information materials in the future [21,22].
Many authors, in particular those working with screening,
downplay or reject even those harms that are arguably the
most important: overdiagnosis and overtreatment. This is
unfortunate, because we know a priori, as stated by the
Director of the UK National Screening Committee, that
"All screening programmes do harm; some can do good as
well" [23]. The most serious harms of screening should
therefore have equal priority to the most important bene-
fit – the reduction in breast cancer mortality – if not a
higher one, as far more people will experience harm than
will benefit [24]. Overdiagnosis and overtreatment were
often downplayed as negligible by authors working with
screening, but they are not. Assuming a reduction in
breast cancer mortality of about 15%, as estimated in the
two most recent systematic reviews [24,25]., and 30%
overdiagnosis as indicated by the randomised trials [24],
screening 2000 women over 10 years would prevent one
breast cancer fatality but turn 10 healthy women into can-
cer patients unnecessarily [24].
Table 3: Number and proportion of the 143 articles eligible for review that mention benefits, mention harms, and acknowledge harms 
of screening
Unblinded analysis Blinded analysis Combined analysis
No. of articles (%) No. of articles (%) No. of articles (%)
Mention benefits 139 (97) 134 (94) 137 (96)
Mention harms 99 (69) 84 (59) 89 (62)
Acknowledge harms 63 (44) 41 (29) 56 (39)
Total 143 (100) 143 (100) 143 (100)
Table 2: Distribution of article types, according to author affiliation (blinded consensus)
Work unrelated to screening Screening-related specialty Working with screening
No. of articles (%) No. of articles (%) No. of articles (%)
Review 8 (17) 1 (4) 9 (13)
Editorial 5 (10) 2 (7) 5 (7)
Original research 30 (63) 22 (81) 53 (78)
Other (e.g. commentaries) 5 (10) 2 (7) 1 (1)
Total 48 (100) 27 (99*) 68 (99*)
*Rounding error: should be 100% of articles.BMC Medicine 2007, 5:12 http://www.biomedcentral.com/1741-7015/5/12
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Even in comprehensive studies, an evaluation of both
benefits and harms of medical interventions is not always
performed, or not always published. One recent example
is the systematic review on mammography screening per-
formed on behalf of the US Preventive Services Task Force
[25]. Although this is the only systematic review per-
formed of all the screening trials after the Cochrane
Review of screening was first published in 2001 [26], it
only evaluated the reduction in breast cancer mortality.
Many of the important harms were mentioned, including
overdiagnosis and overtreatment, but none were quanti-
fied. The first Cochrane Review is another example.
Although the protocol for the review listed use of surgical
interventions (biopsy, tumourectomy and mastectomy)
and use of chemotherapy and radiotherapy as outcomes
to become assessed, the editors of the Cochrane Breast
Cancer Group decided to defer presentation and discus-
sion of these results until further editorial review had been
completed. These data – that demonstrated substantial
overtreatment – were published elsewhere at the time [27]
and they are now also available in the updated Cochrane
Review [24]. The Cochrane Collaboration is aware of the
importance of studying and communicating the harms of
interventions, but even with this in mind and with the
best of intentions, unpleasant findings can delay publica-
tion. The inclusion and quantification of harms such as
overdiagnosis and overtreatment in the updated version
of the Cochrane Review [24] shows, however, that it is
possible to improve reporting and provide a balanced
presentation of benefits and harms of interventions. The
original review was the first to demonstrate that screening
leads to substantial overtreatment, and the estimate of
about 30% overdiagnosis and overtreatment has subse-
quently been supported by large epidemiological studies
[28-31]. and with extended data from the Malmö mam-
mography screening trial [32,33]. Hopefully, the
increased focus on harms of interventions will be reflected
in information material directed towards the public in the
future.
Scientific articles on mammography screening favour
information on the mortality reduction, and prefer to
present this as a relative risk reduction rather than an
absolute risk reduction. A relative risk reduction appears
more impressive, but tends to make lay people, as well as
health professionals, overestimate the obtainable benefit
[34]. This problem is known from scientific articles in
general, and is particularly important in a screening set-
ting as so few will benefit of the total number screened
[35].
We experienced some problems while working on this
study. Following a pilot data extraction from 10 articles,
we realised that simply recording whether or not a harm
was mentioned would provide misleading results. The
context in which the harm appeared (framing) had a
major influence on the impression the reader would get of
its meaning and importance. We therefore decided to
evaluate whether or not the harms were downplayed or
rejected. This decision was made after the completion of
our protocol, but before data extraction began. Our eval-
uation of whether or not a harm was downplayed could
have been influenced by our own views, and others might
disagree. We have therefore included a sample of quotes
to allow the readers to make their own interpretation (see
Proportion of the 143 articles eligible for review that down- play or reject overdiagnosis among those that mention it,  related to author affiliation Figure 2
Proportion of the 143 articles eligible for review that down-
play or reject overdiagnosis among those that mention it, 
related to author affiliation. 1: Authors with no apparent 
conflict of interest. 2: Authors in screening-affiliated specialty 
or funded by cancer charities. 3: Authorsworking with 
screening.
0 33 62 0 33 58 7 1
1231231
0
10
20
30
40
50
60
70
123123123
%
0/1
2/6
8/13
0/9
3/9
7/12
1/14
1/6
6/15
Unblinded Blinded  Combined ananlysis
Number and proportion of the 143 articles eligible for  review that acknowledge overdiagnosis, related to author  affiliation Figure 1
Number and proportion of the 143 articles eligible for 
review that acknowledge overdiagnosis, related to author 
affiliation. 1: Authors with no apparent conflict of interest. 2: 
Authors in screening-affiliated specialty or funded by cancer 
charities. 3: Authors working with screening.
40 11 8 30 12 8 27
1231231
0
5
10
15
20
25
30
35
40
45
123123123
%
17/43
4/37
5/63
9/30
6/50
5/63
13/4
5/27
9/68
Unblinded analysis Combined analysis Blinded analysisBMC Medicine 2007, 5:12 http://www.biomedcentral.com/1741-7015/5/12
Page 6 of 7
(page number not for citation purposes)
Additional file 1). However, the focus on benefits in our
sample is clear, regardless of this analysis.
As the focus of the screening debate changes, the preferred
topics may change as well, and our sample may differ
from a sample taken in a different year. However, we find
it unlikely that this would play any major role, as the inev-
itable problem of overdiagnosis with cancer screening has
been known for decades.
The results of the blinded data extraction generally sup-
ported the findings in the unblinded extraction, but the
trends were less pronounced, as could be expected. We
thought that the results of our combined evaluation
would be somewhere in between the two other results,
but this was not the case for the relation between author
affiliation and the likelihood for acknowledging overdiag-
nosis and overtreatment. This is mainly due to a change in
affiliation for some authors when we did more extensive
searches on the Internet for the combined evaluation.
Conclusion
Scientific articles tend to emphasize the major benefits of
mammography screening over its major harms. This
imbalance is related to the authors' affiliation.
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